LABORATORIOS FARMACEUTICOS ROVI, S.A. from 27/11/2020 to 27/11/2020 27/11/2020 08:20 LABORATORIOS FARMACEUTICOS ROVI, S.A. On business and financial situation The Company releases the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Register number: 610